STAGE III PROSTATE CANCER AJCC V8

This study tests whether adding the drug niraparib to standard hormone therapy after radiation helps control high-risk prostate cancer that hasn't spread far. About 200 men will receive either hormone therapy alone or hormone therapy plus niraparib. The goal is to see if the comb…

This study compares a new, shorter radiation treatment (5 sessions over 2 weeks) to the standard longer course (20-45 sessions over 4-9 weeks) for men with high-risk prostate cancer. The goal is to see if the shorter approach works just as well at preventing the cancer from sprea…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This study tests whether testosterone replacement therapy (TRT) is safe and beneficial for men with low testosterone and early-stage prostate cancer who are on active surveillance. Researchers will track cancer progression, quality of life, and whether men stay on active surveill…

This study compares two different hormone therapy combinations (leuprolide plus abiraterone vs. relugolix plus abiraterone) in men with advanced prostate cancer who are also receiving radiation therapy. The goal is to see which combination causes less damage to the heart and bloo…

This study tests a precise type of radiation called proton therapy for men with high-risk prostate cancer that has spread to lymph nodes. The goal is to see if targeting the tumor and nearby lymph nodes with protons causes fewer bowel and urinary side effects than standard radiat…

This study tests whether a precise, short-course radiation method (SBRT) works as well as a slightly longer radiation approach (hypofractionated radiotherapy) for men whose prostate cancer has come back or spread to a few spots after surgery. About 118 participants will receive o…

This phase III trial tests whether high-dose vitamin D can prevent bone loss in older men with prostate cancer who are receiving hormone therapy (ADT). The study will enroll 240 men aged 50 and older, giving them either high-dose vitamin D or a placebo for one year. Researchers w…

This trial tests whether wrapping the nerves around the prostate with a special tissue allograft during surgery can reduce erectile dysfunction and incontinence. 25 men with localized prostate cancer will receive the wrap during nerve-sparing prostate removal. The study focuses o…

This study tests whether a combined PET/MRI scan using a radioactive tracer can accurately detect if prostate cancer has spread to nearby lymph nodes. Fifty men with high-risk localized prostate cancer will receive the scan before their planned prostate removal surgery. The resul…

This study tests whether a short course of hormone therapy (relugolix) can make PSMA PET/CT scans better at finding prostate cancer that has spread to lymph nodes. About 30 men with high-risk prostate cancer will get the hormone drug for 5, 10, or 15 days before their scan. The g…

This study tests whether a supervised golf exercise program can improve physical function, mental health, and quality of life in prostate cancer survivors who are on hormone therapy. Twenty men aged 55-85 with little or no golf experience will participate. The program includes wa…

This study tests whether two radiation treatments with advanced targeting cause fewer side effects than the usual five treatments for men with localized prostate cancer. About 144 participants will receive either the shorter or standard approach, and researchers will track qualit…

This study compares giving standard prostate cancer treatment at home versus in a clinic for Black men with advanced or metastatic prostate cancer. The goal is to see if home treatment improves patient satisfaction, safety, and reduces stress. Thirty-eight participants will recei…

This phase II trial compares the side effects of two standard treatments for advanced prostate cancer: abiraterone plus prednisone versus darolutamide alone. Researchers will track how many patients experience severe side effects (grade 3 or higher) over the course of treatment. …

This trial tests whether using daily MRI or CT scans to adjust radiation plans in real time can lower side effects for men with localized prostate cancer. 186 participants will receive standard stereotactic body radiation therapy (SBRT) either with or without daily plan adaptatio…

This study tests a new way to deliver radiation for prostate cancer that hasn't spread. By using real-time motion tracking during treatment, doctors hope to target the tumor more precisely and reduce common side effects like urinary and bowel problems. About 80 men with early-sta…

This phase 2 trial tests whether wearing bright white light glasses can reduce fatigue and improve mood in men with advanced prostate cancer who are on hormone therapy. The study will compare immediate use of the light therapy to delayed use in 210 participants. The goal is to he…

This study looks at whether having a trained peer navigator—someone who guides patients through the process—helps African American men with advanced prostate cancer better understand and complete genetic testing. Genetic testing is important for treatment decisions, but many pati…